Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 40

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Oct 28, 2006; 12(40): 6515-6521
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6515

Full Size Figure Download Figure

Figure 1 Immunohistochemically detectable nodal microinvolvement with monoclonal antibody Ber EP4 (×400).

Citation: Yekebas EF, Bogoevski D, Bubenheim M, Link BC, Kaifi JT, Wachowiak R, Mann O, Kutup A, Cataldegirmen G, Wolfram L, Erbersdobler A, Klein C, Pantel K, Izbicki JR. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. World J Gastroenterol 2006; 12(40): 6515-6521
URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6515.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6515

Yekebas EF, Bogoevski D, Bubenheim M, Link BC, Kaifi JT, Wachowiak R, Mann O, Kutup A, Cataldegirmen G, Wolfram L, Erbersdobler A, Klein C, Pantel K, Izbicki JR. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. World J Gastroenterol 2006; 12(40): 6515-6521 [PMID: 17072983 DOI: 10.3748/wjg.v12.i40.6515]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.